21.8.2023 13:36:56 CEST | Aqua Bio Technology ASA | Additional regulated
information required to be disclosed under the laws of a member state

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "
Company") on 8 August 2023 regarding a subsequent offering with gross proceeds
of up to NOK 5,000,001 through issuance of up to 1,666,667 new shares at a
subscription price of NOK 3.00 per share (the "Subsequent Offering"). In the
Subsequent Offering, the shareholders of the Company as of 23 July 2023 (as
registered in the VPS on 25 July 2023), except: (i) shareholders that subscribed
for shares in the private placement placed on 23 July 2023, and (ii)
shareholders who are resident in a jurisdiction where such offering would be
unlawful, or would require any prospectus filing, registration or similar action
(the "Eligible Shareholders"), received subscription rights giving preferential
rights to subscribe for and be allocated new shares in the Subsequent Offering
(the "Offer Shares"). In addition, certain groups of investors, as described in
the stock exchange notice dated 8 August 2023 were given a secondary right to
subscribe for Offer Shares not subscribed for by the Eligible Shareholders.

The application period in the Subsequent Offering ended on 18 August at 16.30
CEST. At the end of the application period, the Company had received
applications corresponding to an oversubscription of approximately 270,000 Offer
Shares. The new shares will be subscribed both through subscription rights and
from Secondary Subscribers.

The Company's board of directors (the "Board") has now allocated shares in the
Subsequent Offering, which implies that the Company shall issue 1,666,667 new
shares related to the Subsequent Offering. The Board has allocated 1,442,978
Offer Shares to Eligible Shareholders and 270,644 Offer Shares to Secondary
Subscribers. Allocation letters, regarding the number of shares allocated and
the subscription amount to be paid, will be distributed to the subscribers
shortly.

Completion of the Subsequent Offering is subject to approval of the share
capital increase pertaining to the Subsequent Offering in the extraordinary
general meeting of the Company to be held on 24 August 2023. Shareholders
representing more than 2/3 of the shares in the Company has entered into voting
undertakings where they have undertaken to vote in favour of such resolution.

For further information, please contact Håvard Lindstrøm, CEO, telephone +47
9413 2288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

 * Håvard Lindstrøm, 004794132288, hl@aquabiotech.no 

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/2553/3557/Download%20announcement
%20as%20PDF.pdf